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Glycosylation is considered as one of the crucial critical quality attributes of therapeutic glycoproteins
and for their biosimilar counterparts. Carbohydrate moieties of such biopharmaceuticals should be
closely monitored during all stages of development and manufacturing and studied accordingly during
comparability or similarity exercises. In therapeutic glycoprotein production, the batch-to-batch alter-
ation in glycosylation represents an excellent indicator of process robustness. Due to the complexity of
the obtained glycoanalytical proﬁle it is challenging to determine and describe the level of similarity
between the N-glycosylation characteristics of two glycoprotein production lots or between the refer-
ence batch and its biosimilar versions. In this tutorial, we provide a step-by-step approach to calculate a
numerical similarity value of N-glycosylation, referred to as Glycosimilarity Index that can be efﬁciently
used to assess the conformity degree of any new N-glycosylation proﬁle to a given target proﬁle.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Considering the increasing role of protein therapeutics in the
pharmaceutical market, proven by the fact that currently most of
the high revenue drugs are monoclonal antibodies, Fc-fusion pro-
teins and glycoprotein based new modalities, their comprehensive
characterization is of high importance [1]. In most therapeutic
mAbs this characterization process means the analysis of the N-
glycosylation present at the conserved Asn297 site located of the
CH2 domain in the Fc region of antibody based molecules. Gener-
ally, these N-glycans are deeply involved in the biological activity,
physicochemical properties and serum half-life of a glycoproteins.
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phoresis-laser induced ﬂuo-
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man).
B.V. This is an open access article ufunctions such as antibody-dependent cellular cytotoxicity (ADCC)
and complement-dependent cytotoxicity (CDC). Another important
sugar residue dependent function of glycosylated biotherapeutics
can be the anti-inﬂammatory effect inﬂuenced by terminal sialy-
lation [2]. Clearance of mAbs are also affected by the type of
glycosylation they carry. For instance, it has been shown that the so
called G0 glycoform (asialo-, agalacto-, biantennary core fucosy-
lated complex N-glycan, also referred to as FA2 by the Oxford
nomenclature [3]), which contains no galactoses and therefore
presents terminal N-acetylglucosamines (GlcNAc), is bound by a C-
type lectin, a mannose receptor, thus, cleared by dendritic cells and
macrophages [4,5]. Similarly, IgGs bearing high mannose-type
glycans exhibit reduced serum half-life [6]. These ﬁndings have
strong implications in therapeutic antibody quality control, sug-
gesting that glycoforms should be carefully controlled, even at low
levels if immunogenic such as the a1-3 Gal or N-Glycolylneur-
aminic acid epitopes. In most instances, the above listed functions
and features are parts of the mode of drug action in relation to their
safety and clearance proﬁle [7]. Therefore, detailed analysis of these
glycans provides important critical quality attribute (CQA)
information.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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terization and monitoring of N-glycans since glycoproteins always
display a heterogeneous set of glycans depending on the genetics of
the host cell line as well as the upstream and downstream bio-
processes. Biotherapeutics are usually developed using the so
called quality by design (QbD) approach, where glycosylation is
often a very important part of the product design as it can enhance
such molecular abilities as increased half-life, speciﬁcity and efﬁ-
cacy. Since glycosylation is not template driven, i.e., not coded in
DNA, predicting glycosylation is very complex and difﬁcult given
the number of factors and cellular processes that must be consid-
ered to obtain the desired glycosylation proﬁle. These factors
include the expression levels of relevant glycosyltransferase/
glycosidase enzymes, the level of monosaccharides and pseudo-
sugars present during fermentation, as well as bioprocessing pa-
rameters, like temperature, pH, O2 and CO2 level, etc.
Thus, comprehensive characterization of all attached N-glycan
structures including positional and linkage information is critical
and should be monitored from early through late stage develop-
ment to commercial manufacturing. WHO guidelines on bio-
therapeutics [8] and the International Conference on
Harmonization (ICH) Q6B [9] mandate also stated that PTMs, such
as glycosylation should be identiﬁed and adequately determined.
Due to the signiﬁcant impacts of the attached carbohydrate struc-
tures on safety and therapeutic efﬁcacy as discussed above, analysis
of the glycan proﬁles of therapeutic glycoproteins is an inseparable
part of the quality control strategy for glycosylated
biopharmaceuticals.
Since, glycosylation is considered to be critical for quality and it
can be easily inﬂuenced by small manufacturing variations or
changes, glycan related attributes must also be assessed during
comparability testing. Consequently, it is also essential for bio-
similars to quantitatively show their resemblance in terms of their
glycosylation to the reference product [10].
Glycan analysis is a challenging task considering the possible
high complexity of these molecules. Their analysis by liquid phase
separation techniques such as liquid chromatography or capillary
electrophoresis is hindered by the lack of chromophore/ﬂuo-
rophore moieties, requiring derivatization, in most cases with
ﬂuorescent tags for enhanced detection sensitivity and speciﬁcity.
For capillary electrophoresis analysis, carbohydrates are labeled by
a charged ﬂuorophore to respectively support their electro-
migration and sensitive detectability [11]. Rapid exploratory and
structural elucidation of the separated sugars is usually accom-
plished by applying the so called glucose unit (GU) value method,
that practically normalizes the migration/elution time of the
separated peaks to an oligosaccharide ladder [12]. The calculated
GU values are then used to search relevant glycan databases (e.g.,
www.GlycoStore.org) and the structures of the individual carbo-
hydrates are suggested/classiﬁed with adequate probability. To
simplify the calculation process and increase precision, bracketing
or the recently introduced triple internal standard based approach
is applied [13]. However, for exact characterization of the separated
glycans, exoglycosidase mediated carbohydrate sequencing and MS
analysis are also important [14,15].
Biosimilars, by deﬁnition, are copy versions of already autho-
rized biological medicinal products with demonstrated similarity in
physicochemical characteristics, efﬁcacy and safety, based on
comprehensive analytical and clinical similarity studies [16]. Gly-
cosimilarity represents a substantial subset of biosimilarity [17] and
it reﬂects to similarity in terms of the glycosylation related critical
quality attributes (gCQAs) especially macro- and micro-
heterogeneity. For therapeutic monoclonal antibodies and Fc
fusion proteins these attributes are usually as follows: afucosylation
level (fucosylation affects ADCC function via FCgRIII binding), totalterminal galactosylation (antennary galactosylation inﬂuences CDC
activity), total sialylation (terminal sialylation enhances anti-
inﬂammatory effects), as well as the amount of high mannose
structures and glycan species having terminal GlcNAc (both for
their potential effect on serum half-life). If present, the analysis and
quantiﬁcation of immunogenic glycan residues are also important
parts of such study focusing on the detection and comparison of the
levels of the following residues: alpha (1,3)galactose, beta (1,2)
xylose, alpha (1,3)fucose and N-glycolylneuraminic acid (Neu5Gc).
2. The glycosimilarity concept
The approach and rules of establishing biosimilarity are deﬁned
by leading regulatory agencies, including but not limited to the US
Food and Drug Administration (FDA) and the European Medicines
Agency (EMA) [18,19]. There are more and more biosimilar candi-
dates have been granted approvals in recent years with the related
documentation (brieﬁng documents, papers with detailed analyt-
ical similarity data sets) publicly available about their analytical
similarity approach and results. Therefore, the major requirements
by the leading agencies nowadays are considered to be relatively
clear across the industry. Both EMA and FDA recommends the use
of a three-tier based approach for the criticality ranking of the
different CQAs. Based on this ranking they suggest to use different
acceptance criteria/quality ranges to the attributes considering
their importance when assessing similarity between the reference
medicinal product (RMP) and its biosimilar candidates. For Tier 1 or
highly critical attributes the FDA suggests the use of equivalence
testing, while EMA recommends the use of quality range (±1.5 SD)
with a 95% conﬁdence level. For Tier 2 ranked attributes a quality
range method is suggested by both agencies that is created using
a ± 3 SD upper and lower limit around the RMP mean also with a
95% conﬁdence. In case of the least critical QAs (Tier 3) graphical or
numerical comparison supposed to be sufﬁcient without a pre-
deﬁned similarity range [18,19]. EMA has also been emphasizing
the importance of testing the reference medicinal product and
biosimilar candidate samples head-to-head in the same assay using
different, preferably orthogonal analytical methods whenever
feasible. Therefore, deﬁning similarity, or more precisely the gly-
cosimilarity, requires a well-deﬁned scoring system and rules for
comparative characterization such as the one introduced several
decades ago by Altman and Bland for measurements in medicine
[20]. Recently, their approach was further developed by Karlsson
et al. [21] to be used for similarity comparisons of surface plasmon
resonance sensorgrams to characterize and compare different
protein interactions.
In this tutorial, an efﬁcient and complex similarity scoring sys-
tem is presented using a step-by-step approach to deﬁne numerical
similarity between the N-glycan proﬁle of a model therapeutic
monoclonal antibody and an artiﬁcially generated spiked test N-
glycan pool. The approach is based on the calculation and combi-
nation of two different similarity scores. The ﬁrst one is the proﬁle
similarity score, which is calculated by comparing each and every
single data points of the normalized electropherogram (or chro-
matogram) of the test item to a pre-deﬁned quality range that is
based on the manufacturing variability of the reference lot. The
second score is the compositional similarity, which is based on
comparing the levels of the different gCQA groups to the similarity
range that is created just like in the previous case based on the
compositional variations of the released N-glycan pool from 6
different manufacturing lots. The mean of these two scores results
in the ﬁnal Glycosimilarity Index (GI). One beneﬁt of using such an
index is in complex DoE studies, used for process development and
process characterization activities or during clone selection, the
Glycosimilarity Index can be used as a single response that
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item to the desired target or reference proﬁle. Using lower number
of responses allow the generation of more simpliﬁed, therefore,
more accurate and reliable models that eventually lead better and
more robust manufacturing processes. In addition, the use of the GI
is also beneﬁcial in comparability and similarity studies and allows
a clear, simple and easy comparison between the two samples and
therefore better decision making. Application of the GI in clone
selection studies enables simple differentiation between the N-
glycosylation proﬁles of the candidates, while in similarity or
comparability studies it will allow easier comparison between the
different manufacturing lots or the biosimilar candidate and its
reference product.3. Theory
Calculation of the similarity scores is based on the approaches of
Altman and Karlsson [20,21]. Percentage scores are generated with
a simple mathematical calculation for considering all data points
(i.e., UV absorbance or ﬂuorescence unit values) for the peaks of
interest, falling inside and outside of the Tier pre-deﬁned tolerance
limits deﬁned by ± SD of the mean value from the different refer-
ence manufacturing lots. Points located inside the limits, regardless
of their distances from the mean are scored with 100% similarity as
shown in Fig. 1 (ﬁrst term in Equation (1)). On the other hand, the
contribution of points falling outside of the tolerance limits are
corrected by using a sum of squared distances to the mean (second
term in Equation (1)). Consequently, the points outside the toler-
ance limits reduce the similarity score.
Ai¼YiþXi,
Xn
j¼1

xuj  xlj

 xj
2

xsj  xj
2 (1)
where, Ai represents the percentage of similarity of attribute i (i¼ 1,
…,n), Yi and Xi represent the percentage of data points inside and
outside of the tolerance limits of that particular attribute, respec-
tively. The upper and lower tolerance limits of point j are repre-
sented by xuj and xlj, respectively. The mean of the jth reference
material points is xj, while, xsj is the jth sample point falling outside
the tolerance limits [17] as shown in Fig. 1. The worked example
below details all the calculation steps for easier understanding.
Linking of the obtained N-glycosylation proﬁle to safety, clear-
ance or efﬁcacy of the product is usually done through the deﬁni-
tion of glycosylation related CQAs (gCQAs). These attributes in most
cases are deﬁned as important subsets of the major N-glycan sub-
types, like total afucosylation, total high mannosylation, total sia-
lylation or total terminal galactosylation, etc. Values are assigned toFig. 1. The glycosimilarity scoring concept. UTL: upthese attributes by summing up the relative percentage of the
amounts of those oligosaccharides having these terminal sugar
residues.
Since the peak area ratio of the different glycans within a gCQA
is also very important, the composition similarity of the released
glycan pool has to be considered as a major attribute. For example,
the composition of the total afucosylation of Fc attached N-glycans
is highly critical in terms of the expected ADCC response. A test
mAb with 10% total afucosylation that only comprises of high
mannose type glycans will have signiﬁcantly different ADCC ac-
tivity than that of a mAb where the 10% of afucosylation is a result
of mainly complex type N-glycans, like G0, G1, G1’ or G2. The
overall glycosylation similarity (Equation (2)), the Glycosimilarity
Index (GI) is composed of the mean of the proﬁle and composi-
tional similarity scores (both are calculated by Equation (1)) and the
proﬁle similarity is always ranked as a very high criticality (Tier 1)
attribute, i.e., on the third power.
GI¼ e
tip,Aip þ
Pn
i¼1etic,Aic
etip þPni¼1etic
(2)
Where n is the number of attributes, Aip is the percent value of the
proﬁle similarity score and Aic is the similarity score of attribute i.
All similarity scores are computed by using Equation (1). ti is the
tier rank factor, which is 3 for high (Tier 1), 2 for moderate (Tier 2)
and 1 for attributes with low criticality (Tier 3). Proﬁle similarity is
always a high criticality (tip ¼ 3) attribute, i.e., e3 ¼ 20.09, while the
tier factor of compositional similarity (tic) can range from 1 to 3, i.e.,
e1 ¼ 2.71, e2 ¼ 7.39 and e3 ¼ 20.09.
In complex molecules containing occupied N-glycosylation sites
at different locations of the molecule such as the fusion protein
etanercept with two conserved N-glycosylation sites in its Fc
portion and 4 distinct sites on the TNFa receptor part, sub-indexes
shall be generated for each site types with different criticality. Thus,
the generation of speciﬁc sub-indexes is required when different
type of N-glycosylation sites are presented with such relevance as
surface exposed sites that has no effect on the primary mechanism
of action and conserved Fc sites affecting effector functions or sites
that related for half-life and stability. These glycosylation sites on
different parts of the protein therapeutic normally differ in their
glycan composition as well as in the criticality of their N-glyco-
sylation related attributes such as total sialylation or total afuco-
sylation. For example, in an Fc fusion protein with signiﬁcant
effector functions, e.g., ADCC, the afucosylation level is considered
to be a high criticality attribute for the Fc linked oligosaccharides
(ti ¼ 3). On the other hand, for sugars attached to the N-glycosyl-
ation sites outside of Fc, this attributes have only very low criticality
(ti ¼ 1). Therefore, these sites ﬁrst have to be grouped based on theper tolerance limit, LTL lower tolerance limit.
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shall be studied separately. When it comes to the calculation of the
glycosimilarity index, it is necessary to calculate different sub-
indexes for each groups. In general terms, lower Glycosimilarity
Index implies greater effect of the observed glycosylation differ-
ences and consequently weaker overall similarity of a biosimilar
candidate.
In practice, the Glycosimilarity Index calculation workﬂow in-
cludes the following steps:
1) Determination of the target proﬁle by characterizing the refer-
ence lots
2) Identiﬁcation of the glycosylation related attributes and
assessment of their criticality
3) Classiﬁcation of gCQAs and deﬁnition of their tolerance limits
4) Compositional and proﬁle similarity scoring
5) Calculation of the Glycosimilarity Index
This tutorial provides a step by step approach for calculating the
Glycosimilarity Index to obtain a single percentage score that rep-
resents the level of similarity between the different N-glycosylation
proﬁles and their effect on safety, efﬁcacy and immunogenicity
relative to a deﬁned reference target proﬁle, that is generated from
multiple lots of the reference product.
4. Glycosimilarity index calculation: A worked example
The referencemAb used for this worked examplewas an isotype
IgG1k monoclonal antibody expressed in CHO cells with intended
target neutralization (Class II) and plausible ADCC function as part
of its mode of action (MoA). It had only one N-glycosylation site in
each heavy chains of the Fc region of the molecule at Asn297. The
N-glycolylneuraminic acid (NGNA) content of the product was
<0.1% of the total sialylation.
Step 1) Determination of the target proﬁle by characterizing the
reference lots
The released and ﬂuorophore labeled glycans from six different
production lots of the commercially available reference therapeutic
mAb were analyzed in triplicates by capillary electrophoresis with
laser induced ﬂuorescent detection (CE-LIF) in two differentFig. 2. N-Glycan proﬁle of the test mAb. Structures of the numbered peakssequences in different days to obtain the batch-to-batch and
analytical variation of both the electropherogram proﬁle and glycan
composition. A representative electropherogram is shown in Fig. 2
with 15 structures identiﬁed based on their GU values (abbreviated
structural names are listed in Table 1, following the Oxford
nomenclature as cited in www.glycostore.org). Glucose unit (GU)
values were assigned for each data points of the electropherogram
by the GUcal software (freely available at www.GUcal.hu) to
accommodate proﬁle similarity calculations. The batch-to-batch
peak area variances of the test mAb N-glycan compositions are
depicted in Table 1.
Step 2) Identiﬁcation of N-glycosylation related attributes and
assessment of their criticality
The type of the biologic and genetic makeup of the host cell line
used in the production of a glycobiotherapeutic drug deﬁnes its N-
glycosylation attributes and their potential variances. Table 2 lists
the abundance of the most important N-linked carbohydrate resi-
dues the various cell lines generate by species. (þþþ) depicts high
abundance, (þþ) the presence, while (þ) low abundance and (±)
both the presence and absence reported in the literature. Terminal
sialylation is an important attribute for anti-inﬂammatory prop-
erties, however, the N-glycolylneuraminic acid (Neu5Gc) subtype is
immunogenic. Similarly, a1,3- Galactosylation (a1,3-Gal) and the
presence of b1,6-xylose and alpha a1,3-core fucose are also
considered as immunogenic residues. The presence of oligo-
mannose structures is reportedly responsible for rapid clearance of
the mAb from serum, suggesting that these structures are exposed
and bind to the mannose receptor expressed by macrophages and
other phagocytic cells [6].
The effects of critical glycan epitope related attributes should be
evaluated based on safety/immunogenicity, biological activity/ef-
ﬁcacy and clearance considerations. Table 3 shows the impact level
of the various mAb sugar residues in view of their criticality. For
example, the a1,3-galactose is highly immunogenic, so (–) reﬂects
its highly negative impact. The core fucose on the other hand is
critical for the biological activity/efﬁcacy via ADCC function, thus
has high impact (þþ). The criticality of some sugar epitopes are not
yet determined or less important reﬂected by the n.d. (not deter-
mined) assignment. Once the criticalities of all CQAs are deﬁned,
their tolerance window should be deﬁned.are listed in Table 1. Conditions are given in the experimental section.
Table 1
Compositional batch-to-batch peak area variations of the test mAb analysis. The
lower panel of the table depicts the percentage distribution of the major glycan
subclasses of interest from glycosimilarity point of view.
Peak No. Structure Lot #1 Lot #2 Lot #3 Lot #4 Lot #5 Lot #6
% % % % % %
1 M3 0.4 0.4 0.3 0.3 0.3 0.4
2 FM3 0.6 0.6 0.3 0.4 0.4 0.3
3 FA1G1S1 0.5 0.5 0.3 0.3 0.3 0.2
4 A2 2.6 2.6 1.9 1.9 2.3 2.2
5 M5 3.5 3.5 2.3 2.3 3.2 2.8
6 FA2G2S1 0.6 0.6 0.3 0.3 0.3 0.2
7 FA2 62.5 62.5 62.4 61.5 66.1 67.3
8 A2[6]G1 2.0 2.0 1.6 1.7 1.8 1.7
9 FA1[6]G1 1.9 1.9 1.3 1.4 1.4 1.5
10 M7 1.8 1.8 1.4 1.5 1.7 1.6
11 FA3 0.5 0.5 0.3 0.3 0.4 0.4
12 FA2[6]G1 14.7 14.7 18.0 18.3 14.2 14.3
13 FA2[3]G1 6.0 6.0 6.8 7.0 5.5 5.4
14 M8 0.5 0.5 0.4 0.4 0.5 0.3
15 FA2G2 1.8 1.8 2.4 2.5 1.6 1.5
S 100 100 100 100 100 100
Terminal Gal % 26.4 26.4 30.0 30.8 24.5 24.3
Afucosylated % 11.0 11.0 8.0 8.1 9.8 9.0
High mannose% 5.9 5.9 4.3 4.2 5.4 4.7
Sialylation% 1.1 1.1 0.6 0.6 0.6 0.4
Terminal GlcNAc % 65.6 65.6 64.6 63.7 68.8 69.9
Table 3
Effects of Fc glycosylation on mAb product quality (PK: pharmacokinetics; PD:
pharmacodynamics [23,24].
N-Glycan attribute Safety/Immunogenicity Biological
activity
Clearance
(PK/PD)
Term. Galactose n.d. þ -
Term. GlcNAc n.d. - -
a1,3-Gal e n.d. n.d.
Core Fucose n.d. þþ n.d.
bisect. GlcNAc n.d. þ n.d.
High-mannose n.d. þ e
Neu5Gc e () þ
Sialylation n.d. () þ
a1,3-core Fuc e n.d. n.d.
b1,6-xylose e n.d. n.d.
þ positive impact; þþ high positive impact; - negative impact; – high negative
impact; (±) potential impact.
Table 4
Glycosylation related critical quality attributes (gCQA) and their tolerance limits.
gCQA N-glycan
Attribute
criticality
Tolerance limit for
proﬁle similarity
Tolerance limit for
compositional
similarity
Terminal Gal % Moderate
(Tier 2)
±3 SD ±3 SD
Total afucosylated % High (Tier 1) ±1.5 SD ±1.5 SD
High mannose % High (Tier 1) ±1.5 SD ±1.5 SD
Sialylation % Low (Tier 3) ±3 SD <3%
Terminal GlcNAc % Low (Tier 3) ±3 SD ±3 SD
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In this exercise, a three Tier based criticality assessment of
quality attributes were used. Classiﬁcation of the different
glycosylation related attributes were based on the abundance and
effect of the certain glycan types to pre-deﬁned mechanisms of
action and on their contribution to the safety and clearance
proﬁle of the reference mAb. Tier 1 (high) includes gCQAs that are
directly impacting the potency of the product, in this instance the
ADCC function (level of core fucosylation) and clearance (high
mannose structures). This required to fall within the mean ± 1.5
SD of the multiple reference product batches tested. Attributes
ranked as Tier 2 has moderate impact on product quality, so the
tolerance limits for these attributes are calculated as mean ± 3.0
SD. Finally, glycan types with low or no signiﬁcant impact at these
abundance levels are controlled by ﬁx upper limits at the
compositional level and mean ± 3.0 SD tolerance limit for proﬁle
similarity calculation.
Based on the three Tier information, the tolerance limits used
for the critical sugar residues for the test mAb are shown in Table 4.
As one can observe, the N-glycan attribute criticality of the totalTable 2
Abundances of N-glycosylation related attributes in different species [22].
N-Glycan attribute CHO BHK NSO, SP2/0 Human Yeast
Sialylation þþ þ þþþ þþ e
a2,6-sialyl e e þ þ e
Neu5Gc þ þþþ þþþ þ/* e
a1,3-Gal e þ þþ e e
bisect. GlcNAc e e e þ e
a1,6-core Fuc þ þ þþ þ e
a1,3-core Fuc e e e e e
b1,6-xylose e e e e e
High-mannose þ þ þ þ þþþ
CHO: Chinese hamster ovary; BHK: baby hamster kidney; NS0: nonsecreting murine
myeloma; SP2: mouse hybridoma cells. þþþ abundant presence þþ presence þ
low presence e not present ± both, presence and absence reported, *possible
presence of Neu5Gc from exogenous sources.afucosylated (i.e., non-core fucosylated) structures are high, thus
have ±1.5 SD tolerance limit for both proﬁle and compositional
similarity. It is important to note that total afucosylation also in-
cludes other structures without core fucose, e.g., high mannose
structures. Actually, in proﬁle similarity assessment the ±1.5 SD
tolerance limit should apply for the high mannose structure subset
anyway, considering its important role in clearance.
First, the relative ﬂuorescence intensities (RFU) of the peaks
were normalized based on the highest peak in the electrophero-
gram to minimize the effects of analytical variability on the calcu-
lated similarity score. GU ranges used in similarity calculationwere
deﬁned based on peak integration and the ranges were set ac-
cording to peak start/end points. The glycosylation related N-glycan
attributes, their criticalities and the corresponding tolerance limits
for the test mAb are listed in Table 5. In case a particular glycan
could be considered in two different attribute groups with different
criticality, the stricter limits were applied during score calculation.
For example, for the total amount of afucosylated structures theTable 5
GU ranges of the individual structures with their tolerance limits.
Peak No. Structure GU range of peaks Tolerance limit
1 M3 6.31e6.75 ±1.5 SD
2 FM3 6.76e6.89 ±3.0 SD
3 FA1G1S1 6.92e7.04 ±3.0 SD
4 A2 (G0) 7.68e7.77 ±1.5 SD
5 M5 7.77e7.85 ±1.5 SD
6 FA2G2S1 7.95e8.44 ±3.0 SD
7 FA2 (G0F) 8.58e8.75 ±3.0 SD
8 A2 [6]G1 8.84e8.99 ±1.5 SD
9 FA1 [6]G1 9.13e9.28 ±3.0 SD
10 M7 9.32e9.53 ±1.5 SD
11 FA3 9.57e9.64 ±3.0 SD
12 FA2 [6]G1 (G1F) 9.65e9.82 ±3.0 SD
13 FA2 [3]G1 (G1'F) 9.95e10.17 ±3.0 SD
14 M8 10.55e10.66 ±1.5 SD
15 FA2G2 (G2F) 11.03e11.18 ±3.0 SD
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structures. Therefore, in proﬁle similarity assessment the ±1.5 SD
tolerance limit was applied for high mannose structures too for this
subset. The Mean as well as the Upper and Lower Tolerance limits
were calculated using the normalized RFUs of the 6 different
reference lots, point-by-point. Data points in the electrophero-
grams outside of the assessed GU ranges (i.e., baseline) were
considered in the similarity score calculation with a ±6.0 SD
tolerance limit.
Step 4) Compositional and proﬁle similarity scoring
To better demonstrate the Glycosimilarity Index calculation
workﬂow, two artiﬁcial N-glycan proﬁles were generated by
spiking the released and APTS labeled test mAb N-glycan pool with
1 and 2 pmol of both APTS labeled Man5 and FA2G2 glycan stan-
dards, referred to as Model 1 and Model 2, respectively. These
models represent increase in the amounts of core fucosylated and
high mannose structures, i.e., change the amounts of these two
gCQAs. Fig. 3, panel A shows the superimposed CE-LIF traces of the
mean proﬁle of the six mAb lots with the spiked glycan pools with 1
and 2 pmol of Man5 and FA2G2 for Model 1 and Model 2, respec-
tively. Panel B depicts the blown-up part of peaks 8e10. As one can
observe in Panel A, the sizes of those two spiked peaks increased,
while the area of the rest of the peaks remained practically un-
changed. More importantly, the added amounts of these two gly-
cans increased the corresponding peak sizes beyond the upper
tolerance limits, consequently resulting in decreased
glycosimilarity.Fig. 3. Superimposed electropherograms (panel A) of the released and APTS labeled six m
FA2G2 for Model 1 (red trace) and Model 2 (blue trace), respectively. Panel B depicts the blo
the mean as well as the upper and lower tolerance limits, respectively. The other color traCompositional similarity scores were calculated by Equation (1)
using the concept delineated in Fig. 1. Table 6 depicts the N-
glycosylation attributes of the major glycan subtypes of Terminal
Gal %, Total afucosylated %, High mannose %, Sialylation % and
Terminal GlcNAc % for the mean of the 6 lots, as well as for the two
Model mixtures. The compositions were calculated for Model 1
spiked by 1 pmol and Model 2 spiked by 2 pmols of FA2G2 and
Man5, each. As an example, the limit distance for the Tier 1 gCQA
total afucosylated structures (second line in Table 6) with the mean
value of 9.5 were LD ¼ 2.0, thus, the lower tolerance limit (LTL) was
9.5e2 ¼ 7.5; while the upper tolerance limit (UTL) was
9.5 þ 2 ¼ 11.5. After spiking with 1 pmol Man5 and FA2G2, the
mean increased from 9.5 to 14.5, with the corresponding differ-
ences of 5 units. Considering the 2-unit limit distance (LD), the
compositional similarity (CS) % score for this attribute was calcu-
lated based on Equation (1) as follows: 100 x (22/52)¼ 16.3, where 2
is the limit distance and 5 is the actual distance from the mean. The
compositional similarity scores for the four other attributes were
calculated similarly, considering 100% when the data points fell
within the LTL and UTL and using the calculation scheme above for
the other ones when the data points fell outside of the LTL and UTL.
For the rest of the subtypes, this calculation resulted in 100% for
Terminal Gal%, 23.8% for High Mannose, 100% for Sialylation and
86.7% for Terminal GlcNAc N-glycosylation attributes.
In proﬁle similarity calculation, the three small peaks high-
lighted by the gray box in Fig. 3 (in the GU range of 8.58e9.65) were
ﬁrst assessed among the traces. Panel B in Fig. 3 depicts the blown
up superimposed traces of the separation of the 6 test mAb lots for
the individual peaks of 8, 9 and 10 with the median (dotted line)Ab lots (black trace) with the spiked glycan pools containing 1 and 2 pmol of M5 and
wn-up part of peaks 8e10 with the black dotted and the red dotted lines representing
ces correspond to the 6 production batches analyzed in the study.
Table 6
Calculated compositional Similarity (CS) score values.
N-glycosylation attributes Mean SD LTL UTL LD Model 1 CS% score Model 1 Model 2 CS% score Model 2
Terminal Gal % 27.1 2.7 18.8 35.3 8.1 (3SD) 30.1 100 33.5 100
Total afucosylated % 9.5 1.3 7.5 11.5 2.0 (1.5SD) 14.5 16.3 17.2 6.8
High mannose % 5 0.8 2.7 7.4 1.2 (1.5SD) 9.9 23.8 13.1 8.7
Sialylation % 0.7 0.3 0 1.6 0.9 (3SD) 0.7 100 0.6 100
Terminal GlcNAc % 66.4 2.5 59 73.7 7.5 (3SD) 58.5 86.7 52.1 26.8
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in Table 5. The corresponding structures for these peaks were 8: A2
[6]G1 (terminal galactosylated afucosylated), 9: FA1 [6]G1 (termi-
nal galactosylated fucosylated) and 10: M7 (high mannose) struc-
tures, all within the predeﬁned tolerance limits of ±1.5, ±3.0
and± 1.5, respectively. Therefore, considering each and every single
data points of these peaks, based on the scheme of Fig. 1, all fell
within the predeﬁned tolerance limits. The corresponding calcu-
lation by Equation (1) resulted in 100% proﬁle similarity scores for
these peaks, as the ﬁrst term was 100% (all data points were inside
the tolerance limits) and the second termwas zero (no data points
were outside of the tolerance limits). The same was true for all
other features within the tolerance limits, i.e., for peaks 1e4, 6,7
and 11e14. Proﬁle similarities were calculated for each and every
single data points the same way for the spiked peaks of 5 (Man 5)
and 15 (FA2G2). As one can see in Fig. 3 the Man 5 (peak 5) and
FA2G2 (peak 15) peaks of both spiked traces exceeded the upper
tolerance limit, thus, the second term of Equation (1) kicked in and
decreased the proﬁle similarity scores for Model 1 and Model 2, to
84.2% and 80.2% respectively.
Step 5) Calculation of the Glycosimilarity Index
The Glycosimilarity Indexwas then calculated by using Equation
(2), taking in account of the proﬁle and compositional similarity
scores calculated above. The corresponding numbers for Worked
Example Model 1 in Equation (2) were as follows:GI1¼
etip,Aip þ
Pn
i¼1e
tic,Aic
etip þPni¼1etic
¼ 20:09,84:2 þ ð7:39,100 þ 20:09,16:3 þ 20:09,23:8 þ 2:71,100 þ 2:71,86:7Þ
20:09 þ ð7:39 þ 20:09 þ 20:09 þ 2:71 þ 2:71Þ ¼51:21%where etip ¼ 2.713 ¼ 20.09, Aip is the percent value of the proﬁle
similarity score (84.2), and Aic is the similarity score of the pre-
deﬁned attributes of Terminal Gal % (e2 x 100%), Total afucosylated
%, (e3 x 16.3%) Highmannose % (e2 x 23.8%), Sialylation % (e1 x 100%)
and Terminal GlcNAc % (e1 x 86.7%). All similarity scores were
computed by Equation (1). Similar calculation for Model 2 resulted
in GIModel 2 ¼ 41.12%.5. Discussion
The Glycosimilarity Index gives a percentage score on the
similarity of the N-glycosylation patterns in comparability and/or
biosimilarity studies of glycosylated therapeutic proteins. The use
of this approach makes comparisons easily quantiﬁable in
manufacturing between pre- and post-change batches or be-
tween the innovator and their biosimilar counterparts. This type
of similarity scoring can also be used in system suitability testing
when criteria such as “comparable/similar to reference standard”
is used, allowing the speciﬁcation of exact and objectivenumerical limits instead of subjective comparisons by the ana-
lysts. Using proﬁle similarity scoring only can be a good approach
to assess system suitability in N-glycan proﬁling assays by
calculating and comparing exact values when assessing the
comparable/similar to reference standard criteria. Please note
that the type of the biologic and genetic makeup of the host cell
line as well as the developed manufacturing process deﬁnes the
N-glycosylation attributes and their potential variances. In the
Worked Example of this study, only well-deﬁned and character-
ized proﬁles were compared with relatively small variances for
easier demonstration of the workﬂow. Based on the calculated
compositional and proﬁle similarity scores, the Glycosimilarity
Index for Models 1 and 2 were 51.21% and 41.12%, respectively,
both falling well below 80% [17], thus, exhibiting weak similarity
in their N-linked glycan proﬁles, suggesting that the generated
models would have signiﬁcant differences in their Fc mediated
functions and/or their contribution to clearance.
The Glycosimilarity Index (GI) also holds the potential to
simplify and facilitate decision making for the biopharmaceutical
industry during clone selection or process development studies
representing all glycosylation proﬁle changes with a single score.
This makes the application of the Glycosimilarity Index extremely
beneﬁcial in design of experiment (DoE) models, where glycosyl-
ation changes can be deﬁned as a single outcome only. This sim-
pliﬁes the models without the loss of important information and
allows to create more robust and reduced dimensional design
spaces.6. Experimental
6.1. Chemicals and reagents
The Fast Glycan Sample Preparation and Analysis kit was from
Sciex (Brea, CA). APTS labeled oligomannose 5 (Man5) and asialo-,
galactosylated biantennary complex N-glycan, core-substituted
with fucose (FA2G2) were from Prozyme (Hayward, CA). The
PNGase F enzyme was from Asparia Glycomics (San Sebastian,
Spain). The sodium cyanoborohydride (1 M, in THF) and all other
chemicals were obtained from Sigma-Aldrich (St Louis, MO).6.2. Reference mAb and sample preparation
Six batches of the test monoclonal antibody (Isotype IgG1k)
expressed in CHO cells with the intended mode of action of Class
II (target neutralization) with plausible ADCC function were
subject to glycosimilarity scoring in the Worked Example. The test
mAb had only one N-glycosylation site at the conserved Asn297
A. Szekrenyes et al. / Trends in Analytical Chemistry 122 (2020) 1157288on the Fc region of the molecule in both of the heavy chains. The
N-glycolylneuraminic acid (NGNA) content of the product was
<0.1% of total sialylation. Sample preparation followed the pro-
tocol of the Fast Glycan Analysis kit of Sciex. Models 1 and 2 were
spiked pools of the 6 batches by the addition of 1 and 2 pmol of
both Man5 and FA2G2 glycans, respectively. In all experiments
the Fast Glycan Sample Preparation and Analysis kit was used
with the respective reagent/buffer compositions and CE separa-
tion parameters.6.3. CE-LIF analysis
In all separation experiments a PA 800 Plus Pharmaceutical
Analysis System (Sciex) with laser induced ﬂuorescent detection
(lex ¼ 488 nm / lem ¼ 520 nm) was used with 50 mm internal
diameter (365 mm outside diameter) bare fused-silica capillary
column (effective length: 50 cm, total length: 60 cm). The applied
electric ﬁeld strength was 500 V/cm in reversed polarity mode
(cathode at the injection side) at 30 C separation temperature. A
water pre-injection by 3.0 psi for 5.0 s was followed by the injection
of the sample (2.0 kV for 2.0 s) and the bracketing standardmixture
of maltose and maltopentadecaose (1.0 kV for 1.0 s). For data
acquisition and processing, the 32 Karat software, version 10.1
(Sciex) was used. Glucose unit values were determined by the freely
available GUcal software (www.GUcal.hu).Acknowledgment
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